- Home
- RVSB vs KZIA Comparison
RVSB vs KZIA Comparison
Compare RVSB & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSB | KZIA |
|---|---|---|
| Founded | 1923 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 93.2M |
| IPO Year | 1997 | 2002 |
Fundamental Metrics
Financial Performance| Metric | RVSB | KZIA |
|---|---|---|
| Price | $5.07 | $7.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $17.67 |
| AVG Volume (30 Days) | 39.0K | ★ 183.8K |
| Earning Date | 04-28-2026 | 11-07-2025 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $9.82 | N/A |
| P/E Ratio | $28.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $0.64 |
| 52 Week High | $6.59 | $17.40 |
Technical Indicators
Market Signals| Indicator | RVSB | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 53.04 |
| Support Level | $5.03 | $7.54 |
| Resistance Level | $5.19 | $8.17 |
| Average True Range (ATR) | 0.13 | 1.08 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 10.20 | 27.64 |
Price Performance
Historical ComparisonAbout RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.